1 / 21

New Diabetes Medications

New Diabetes Medications. Sniffy Insulin and Lizard Spit. Hilary Suzawa Med/Peds August 2006. Money! Money! Money!. Diabetic drug market $15 billion today Expected to be $25 billion in 2011 Cost $1500-2000 per year per patient for the new medications. Pathophysiology.

adamdaniel
Télécharger la présentation

New Diabetes Medications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Diabetes Medications Sniffy Insulin and Lizard Spit Hilary Suzawa Med/Peds August 2006

  2. Money! Money! Money! • Diabetic drug market $15 billion today • Expected to be $25 billion in 2011 • Cost $1500-2000 per year per patient for the new medications

  3. Pathophysiology • It’s more than just insulin • An oral glucose load stimulates higher insulin secretion than an equal or higher IV glucose load • Something in the GI tract stimulates insulin • Incretin hormones are peptide hormones secreted by enteroendocrine cells that line the GI tract

  4. Other Hormones • GI secreted –Incretins • Gastric inhibitory peptide aka glucose-dependent insulinotropic peptide (GIP) • Glucagon-like peptide-1 and -2 (GLP-1, GLP-2) • In DM type II • GIP levels are normal but peptide loses its ability to stimulate insulin secretion (function) • GLP-1 levels are decreased (quantity) • GLP-1 is rapidly inactivated by enzyme dipeptidyl peptidase-IV (DPP-IV) • Islet cell secreted—Amylin

  5. Incretins • Stimulate glucose-dependent insulin secretion • Increase insulin in response to meals • Lower risk of hypoglycemia • Suppresses inappropriate glucagon secretion • Increases Beta cell growth and replication • Slows gastric emptying • May decrease food intake (satiety)

  6. Amylin • Suppresses glucagon secretion • especially postprandial • Decreases postprandial hepatic GLC production • Decreases postprandial GLC levels • Reduces gastric emptying time • Centrally-mediated induction of satiety • In DM type II, Amylin secretion delayed and decreased (quantity)

  7. New Kids on the Block

  8. Flew Under the Radar • Pramlintide (Symlin) • Amylin mimic • FDA approved 3/2005

  9. Exenatide (Byetta): GLP-1 mimic • Approved 6/2004 • Synthetic version of exendin-4 (isolated from the venom of the Gila monster) • Mechanism: Binds to GLP-1 receptor (mimic) • Resistant to DPP-IV and so has increased half-life

  10. Exenatide (Byetta) • Injection (subcutaneous) • Pre-filled pen; 250 mcg/ml • Dose • 5 mcg BID within 60 minutes prior to a meal • After one month may increase to 10 mcg BID • Currently BID but may soon have a weekly formulation (Exenatide LAR)

  11. Exenatide (Byetta) • Most common side effect: Nausea • Benefits • Weight loss • Low risk of hypoglycemia • Animal studies—may help pancreas re-grow cells • Efficacy • When added to sulfonylureas or metformin additional lowering of HbA1c by 0.5-1% • Renal excretion

  12. Inhaled Insulin (Exubera) • FDA approved 1/2006 • Inhaled • Dose • 0.05 mg/kg (round down) TID within 10 minutes of a meal • 1 mg and 3 mg blisters • Three 1 mg blisters gives higher level than one 3 mg blister • Give two 1 mg blisters instead of one 3 mg blister if need to substitute

  13. Inhaled Insulin (Exubera) • Side Effects • Respiratory sx, decreases in PFTs (baseline recommended) • Chest pain • Hypoglycemia • Xerostomia and Rash • Otitis media and ear pain (pediatrics) • If current smoker or quit within past 6 months then increased absorption may lead to increased risk of hypoglycemia • Renal excretion

  14. Gliptins (DPP-IV inhibitor) • (Vildagliptin) Galvus & (Sitagliptin) Januvia • Inhibits the destruction of GLP-1 (DPP-IV inhibitor; dipeptidyl peptidase IV inhibitor) • Raise levels of the hormone GLP-1 • Causes the pancreas to produce more insulin • Not as efficacious as metformin • Use as adjunct instead of sulfonylureas (avoid hypoglycemia and weight gain)

  15. Vildagliptin (Galvus) • Dose • 50 mg po daily or 50 mg po BID • Increased GLP-1 and GIP in DM type I and DM type II • Decrease triglycerides • Improved insulin sensitivity • Most common side effect: • Mild hypoglycemia

  16. Sitagliptin (Januvia) • Dose • 100 mg po daily or 200 mg po daily • Renal excretion

  17. Pramlintide (Symlin) • Synthetic analog of human amylin • Mechanism: Supresses glucagon • Adjunctive therapy • Decrease insulin dose by 50% when add Symlin • Dose • Type I: 15 mcg immediately before meals, increase to target 30-60 mcg • Type II: 60 mcg immediately before meals, increase to target 120 mcg

  18. Pramlintide (Symlin) • Side effects • Hypoglycemia (*boxed warning) • Nausea • Headache • Benefits • Weight loss

  19. Key Points • New medications are adjuncts and do not replace insulin or glucophage (Metformin) as mainstays of treatment • Many of the medications are given with meals • Exenatide (Byetta) may help with weight loss • Inhaled insulin (Exubera) may cause respiratory sx and must check baseline PFTs • Vildagliptin (Galvus) and Sitagliptin (Januvia) not yet on the market • Must decrease insulin dose 50% if add Pramlintide (Symlin) because of hypoglycemia

  20. Bibliography • Berenson, A. 4 Diabetes Drugs are Seen Raising Hope and Profit. New York Times June 22, 2006. • Jeha G and Heptulla R. Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations. Pediatric Diabetes 2006: 7: 122-138. • Trujillo J. Incretin hormones in the treatment of type 2 diabetes. Formulary March 2006: 41: 130-141 • Up to Date • http://www.glucagon.com

  21. The End

More Related